30 Apr 2019

Mereo BioPharma Group plc

("Mereo" or the "Company" or the "Group")

Notification of Director Dealing

 

London, April 30, 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 29 April 2019, Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma, purchased 6000 American Depositary Shares (ADSs) at a total price of USD5.887 per ADS.

In addition, Richard Jones, Chief Financial Officer of Mereo BioPharma, purchased 2025 American Depositary Shares (ADSs) at a price of USD6.04 per ADS.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows

1

Details of the person discharging managerial responsibilities

a)

Name

Denise Scots-Knight

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)

 

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD5.87

USD5.90

3000

3000

 

 

d)

Aggregated information:  volume, Price

Aggregated volume: 6000  

Aggregated price: USD5.887

e)

Date of the transaction

2019-04-29

f)

Place of the transaction

XNMS

 

 

1

Details of the person discharging managerial responsibilities

a)

Name

Richard Jones

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

ADS

 

b)

Nature of the transaction

Purchase  

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD6.04

2025

 

 

 

d)

Aggregated information:  volume, Price

Aggregated volume: 2025  

Aggregated price: USD6.04

e)

Date of the transaction

2019-04-29

f)

Place of the transaction

XNMS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END